article
25 March 2020 | By Colin Brown (Newcells Biotech), Sandy Primrose (Newcells Biotech)
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…